By Jade Martinez-Pogue ( November 15, 2023, 5:06 PM EST) -- Late-stage biopharmaceutical company Lenz Therapeutics, advised by Wilson Sonsini Goodrich & Rosati PC, on Wednesday announced that it has agreed to merge with gene editing company Graphite Bio Inc., advised by Goodwin Procter LLP, in an all-stock deal that will result in a publicly traded company with approximately $225 million of cash....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.